{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:23:42Z","timestamp":1786983822173,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018555","name":"Science and Technology Program of Guizhou Province","doi-asserted-by":"publisher","award":["ZK [2022] General 410"],"award-info":[{"award-number":["ZK [2022] General 410"]}],"id":[{"id":"10.13039\/501100018555","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Analytical Biochemistry"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ab.2023.115230","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T10:52:25Z","timestamp":1688813545000},"page":"115230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A high-throughput UHPLC-MS\/MS method for the determination of eight anti-tumor drugs in plasma"],"prefix":"10.1016","volume":"676","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8643-0957","authenticated-orcid":false,"given":"Yao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minzhen","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxingyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ab.2023.115230_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coph.2020.09.007","article-title":"Therapeutic drug monitoring of anti-tumor necrosis factor agents: lessons learned and remaining issues","volume":"55","author":"Wang","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ab.2023.115230_bib2","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ab.2023.115230_bib3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1365-2125.2012.04237.x","article-title":"Monitoring drug therapy","volume":"73","author":"Buclin","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ab.2023.115230_bib4","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ab.2023.115230_bib5","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ab.2023.115230_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27618","article-title":"Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib","volume":"66","author":"Ramsey","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ab.2023.115230_bib7","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1097\/MPH.0000000000001816","article-title":"Concurrent imatinib dosing with high-dose methotrexate leads to acute kidney injury and delayed methotrexate clearance in pediatric patients with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia","volume":"43","author":"Pommert","year":"2021","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ab.2023.115230_bib8","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/10428194.2023.2189803","article-title":"Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia","volume":"64","author":"Cassaday","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ab.2023.115230_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10549-018-05100-z","article-title":"Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM\/2010-04 study","volume":"174","author":"Ocana","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ab.2023.115230_bib10","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00280-006-0334-2","article-title":"The effect of hydroxyurea on P-glycoprotein\/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate","volume":"59","author":"Oostendorp","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ab.2023.115230_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105355","article-title":"A physiologically based pharmacokinetic-pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug -drug interactions of paclitaxel in cancer patients","volume":"150","author":"Mendes","year":"2020","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ab.2023.115230_bib12","first-page":"668","article-title":"Association between circadian and chemotherapeutic cycle effects on plasma concentration of 5-fluorouracil and the clinical outcome following definitive 5-fluorouracil\/cisplatin-based chemoradiotherapy in patients with esophageal squamous cell carcinoma","volume":"17","author":"Kuwahara","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ab.2023.115230_bib13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00280-019-04006-x","article-title":"A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions","volume":"85","author":"de Rouw","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ab.2023.115230_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114380","article-title":"Ultra-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of 12 anti-tumor drugs in human plasma and its application in therapeutic drug monitoring","volume":"206","author":"Li","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ab.2023.115230_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225225","article-title":"Development and validation of LC-MS\/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients","volume":"14","author":"Iacuzzi","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ab.2023.115230_bib16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/00045632211031284","article-title":"A rapid LC-MS\/MS assay for the measurement of serum methotrexate in patients who have received high doses for chemotherapy","volume":"58","author":"McTaggart","year":"2021","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.ab.2023.115230_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2016.10.021","article-title":"Highly sensitive LC-MS\/MS methods for urinary biological monitoring of occupational exposure to cyclophosphamide, ifosfamide, and methotrexate antineoplastic drugs and routine application","author":"Canal-Raffin","year":"2016","journal-title":"J. Chromatogr., B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.ab.2023.115230_bib18","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00216-011-5157-2","article-title":"Wipe sampling procedure coupled to LC-MS\/MS analysis for the simultaneous determination of 10 cytotoxic drugs on different surfaces","volume":"402","author":"Nussbaumer","year":"2012","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ab.2023.115230_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2021.122752","article-title":"Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC-MS\/MS in human plasma: application to therapeutic drug monitoring in patients with non-small cell lung cancer","volume":"1175","author":"Zhou","year":"2021","journal-title":"J. Chromatogr., B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.ab.2023.115230_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22940","article-title":"Comparison of performance characteristics between high-performance liquid chromatography and latex agglutination turbidimetric immunoassay for therapeutic drug monitoring of zonisamide","volume":"33","author":"Eto","year":"2019","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.ab.2023.115230_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25174026","article-title":"Review of chromatographic methods coupled with modern detection techniques applied in the therapeutic drugs monitoring (TDM)","volume":"25","author":"Tuzimski","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ab.2023.115230_bib22","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.2147\/DDDT.S271568","article-title":"Development and validation of UHPLC-MS\/MS assay for therapeutic drug monitoring of high-dose methotrexate in children with acute lymphoblastic leukemia","volume":"14","author":"Lian","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ab.2023.115230_bib23","series-title":"Biological Samples Quantitative Analysis Method Validation Guidelines","article-title":"The pharmacopoeia of people's Republic of China","year":"2015"},{"key":"10.1016\/j.ab.2023.115230_bib24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpba.2017.11.060","article-title":"High throughput routine determination of 17 tyrosine kinase inhibitors by LC-MS\/MS","volume":"150","author":"Merienne","year":"2018","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.ab.2023.115230_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8051","article-title":"Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced non-small cell lung cancer (NSCLC) patient","volume":"33","author":"Joerger","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ab.2023.115230_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood-2009-10-247965","article-title":"Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951","volume":"116","author":"De Moerloose","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ab.2023.115230_bib27","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jpba.2018.12.014","article-title":"A convenient strategy to overcome interference in LC-MS\/MS analysis: application in a microdose absolute bioavailability study","volume":"165","author":"Yuan","year":"2019","journal-title":"J. Pharmaceut. Biomed. Anal."}],"container-title":["Analytical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003269723001951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003269723001951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T12:00:12Z","timestamp":1762084812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003269723001951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":27,"alternative-id":["S0003269723001951"],"URL":"https:\/\/doi.org\/10.1016\/j.ab.2023.115230","relation":{},"ISSN":["0003-2697"],"issn-type":[{"value":"0003-2697","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A high-throughput UHPLC-MS\/MS method for the determination of eight anti-tumor drugs in plasma","name":"articletitle","label":"Article Title"},{"value":"Analytical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ab.2023.115230","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115230"}}